Recursion Pharmaceuticals, Inc. Q3 2026 Earnings Recap

Recursion shares fell 3.9% after earnings, suggesting investors focused on the early, limited clinical evidence rather than the company’s platform and partnership progress. REC-1245 has shown only a small number of partial responses, while the transcript provides no new financial or clinical guidance that clearly explains the selloff.

Key Takeaways

• REC-4881’s updated FAP data showed continued reductions in polyp burden, including in the upper GI tract and among larger, higher-risk polyps; management reported mostly Grade 1 or 2 adverse events and no additional discontinuations.
• REC-1245 showed early single-agent activity in heavily pretreated solid-tumor patients: two confirmed and one unconfirmed partial response.
• Sanofi optioned a potential first-in-class oral I&I candidate; phase I is expected to begin in 2027, and the option triggered a $10 million payment.
• Recursion said it completed a $200 million financing, expects cash runway into 2029, lowered 2026 cash operating expense guidance from $390 million to $375 million, and expects 2027 expense below $360 million.
• The company cited operating-efficiency gains, including 80%–90% fewer compounds synthesized versus industry benchmarks and trial enrollment 30%–60% faster.